BioSpace News Archive

CRISPR Reorganizes CAR-T Pipeline Ahead of FDA’s Landmark Decision

The gene editing company is dropping two programs and favoring its next-generation assets CTX112 and CTX131, which it will continue to develop in oncology but will also test in autoimmune diseases.

December 5, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior

In this third episode of Denatured’s series on AI in drug discovery, we discuss patient behavior and its influence on clinical trials and AI models with guests from GSK, IQVIA, Exelixis and DataHow.

December 5, 2023
·
1 min read
·
BioSpace Insights
J&J Expects Up to 6% Growth Next Year with 20-Plus New Drugs by 2030

Ten of the anticipated assets have the potential to deliver $5 billion or more in peak year sales, while another 15 of the candidates have a $1 billion to $5 billion PYS potential, according to Johnson & Johnson.

December 5, 2023
·
2 min read
·
Kate Goodwin
Drug Development

Alto’s Neuropsychiatric Platform Scores Third Mid-Stage Win

ALTO-300 was significantly more effective in major depressive disorder patients with a specific EEG biomarker than in those without, according to results from an Alto Neuroscience Phase IIa study.

December 5, 2023
·
2 min read
·
Tristan Manalac
Updated: Radiopharmaceuticals Market Predicted to Grow Rapidly Over Next Decade

Fueled partly by increasing lifespans and cancer incidence, the area’s worth is projected to soar to 13.67 billion by 2032, Precedence Research reports.

December 5, 2023
·
5 min read
·
Patience Asanga
Policy

FDA Puts Clinical Hold on Roche BTK Inhibitor Multiple Sclerosis Program

The regulator placed a partial clinical hold on Roche’s fenebrutinib—being developed for relapsing MS—after two patients experienced elevated hepatic transaminase and bilirubin levels indicative of liver injury.

December 5, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Roche Gets Phase III Breast Cancer Victory for Inavolisib Combo

A combination of Roche’s investigational treatment with Ibrance and fulvestrant met its primary endpoint of progression-free survival in the first-line setting in treating PIK3CA-mutated breast cancer.

December 5, 2023
·
2 min read
·
Tyler Patchen
Pharm Country

SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock - December 05, 2023

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced the pricing of an underwritten public offering of 9,482,758 shares of its common stock at a public offering price of $29.00 per share.

December 5, 2023
·
5 min read
Drug Development

J INTS BIO Gives Presentation of Phase 1/2 study of ‘JIN-A02', a Novel Oral 4th Generation EGFR TKI, at ESMO Asia 2023

J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI ‘JIN-A02' were presented at the ESMO Asia 2023 conference held in Singapore from 1st to 3rd December 2023.

December 5, 2023
·
1 min read
Drug Development

EsoCap reports positive topline results from ACESO Phase II trial investigating ESO-101 in eosinophilic esophagitis

EsoCap AG announced that the ACESO Phase II study comparing ESO-101 to placebo for the treatment of eosinophilic esophagitis has met its primary endpoint by significantly reducing the peak eosinophil count in the histological assessment of esophageal biopsies.

December 5, 2023
·
7 min read